An FDA advisory committee has recommended against the approval of an experimental weight-loss drug. Again!
Today it was Arena Pharmaceuticals’ lorcaserin under the advisory panel’s scrutiny. On the key question of whether the benefits of the drug outweigh the risks when used long-term in a population of overweight and obese individuals, 5 committee members voted yes and 9 voted no.
Today it was Arena Pharmaceuticals’ lorcaserin under the advisory panel’s scrutiny. On the key question of whether the benefits of the drug outweigh the risks when used long-term in a population of overweight and obese individuals, 5 committee members voted yes and 9 voted no.
2 commentaires:
C'est toujours de même esti...
La dernière trade en after est à 2.22$
triste pour ceux qui y ont mit "trop" de fric mais ils connaissaient les risques.
Enregistrer un commentaire